Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Thymulin: does it work, is it legal, and what does it cost?

Zinc dependent thymus hormone (9 amino acids) with 1980s rheumatoid arthritis trials and rodent anti-inflammatory data; never approved, never nominated to FDA.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

Quick answers

Quick answers about Thymulin
Does it work in people?Evidence: Human RCT evidence

At least one randomized human trial in PubMed. See the evidence

Is it legal?Regulatory: Not eligible for compounding

Not FDA approved and not on FDA's list of substances pharmacies may compound (the 503A bulks list), so a pharmacy has no federal basis to compound it. [6] [7] See legal status

What does it cost?Not available through licensed channels.
Side effects?Minimal adverse effects reported in the 1987 rheumatoid arthritis trials. No modern human safety data. Injection site reactions reported anecdotally. See side effects and interactions
Tested athlete?WADA: WADA prohibited

What is Thymulin?

Thymulin is a nine amino acid hormone made by the thymus, the gland where immune T cells mature, that requires zinc to be biologically active and helps T cells mature. Its clinical record is thin and old: two small double blind trials (neither patients nor doctors knew who got the drug) published in 1987 found a synthetic form (nonathymulin) at 5 mg daily improved rheumatoid arthritis in 56% of patients versus 17% on placebo, but development stopped and no modern trial exists, while more recent rodent work shows analgesic (pain relieving) and anti-inflammatory effects. It is not approved anywhere, has never been nominated for FDA's compounding lists, and falls under WADA's S0 prohibition on unapproved substances.

Thymulin is a zinc dependent nonapeptide (9 amino acids) hormone produced by thymic epithelial cells. It is also known as Facteur thymique serique (FTS), Serum thymic factor, FTS-Zn, Nonathymulin, Thymic nonapeptide, pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn.

How does it work?

Thymulin binds zinc in a one to one complex, and only the zinc bound form is active. It promotes differentiation of T cell precursors, modulates T cell subsets and natural killer activity, and is regulated by pituitary hormones such as growth hormone and prolactin, so it is considered part of a thymus to neuroendocrine axis. Rodent studies show it reduces pro-inflammatory cytokines and pain behaviors, possibly through effects on glial and immune cells.

Key facts
ClusterImmune and antimicrobial
RoutesInjection (1987 trials); Subcutaneous injection and intranasal (as sold, not from published trials)
Conditions studiedInflammation and inflammatory bowel disease; Peripheral and small fiber neuropathy; Immune support and immune deficiency; Autoimmune disease; Chronic pain
Recordv2, reviewed, verified Sep 29, 2026

What does the evidence say about Thymulin?

Evidence: Human RCT evidenceGrade assigned per the methodology.

Human evidence comes from two double blind placebo controlled trials in rheumatoid arthritis reported together in 1987 (Amor et al.), which compared nonathymulin 1, 5, and 10 mg daily and found the 5 mg dose produced clinical improvement by global assessment in 56% of patients versus 17% on placebo with minimal adverse effects. The work was not replicated and no trial has been published since. Preclinical work by Dardenne, Bach, and later groups characterized the zinc dependence and, in rodents, anti-inflammatory and analgesic effects of thymulin and a synthetic analog. PeptideAgent grades the evidence human RCT on the strength of the 1987 trials but notes they are small, old, and unconfirmed.

Indexed studies by evidence grade
Evidence typeIndexed studiesParticipants (human)
Human randomized trials1n/a
Human observational studies0n/a
Animal studies3n/a
All indexed studies4n/a

Human evidence

Amor 1987: two randomized double blind placebo controlled trials in rheumatoid arthritis compared nonathymulin at 1, 5, and 10 mg per day; the 5 mg dose gave significant clinical improvement (56% of all entered patients improved by global assessment versus 17% on placebo, p below 0.02) and improvement in four objective measures, with minimal side effects and no clear change in immune parameters. No subsequent controlled trial of thymulin in any condition has been indexed. Circulating thymulin levels have been measured as a marker of thymic function in aging, zinc deficiency, and malnutrition, which is observational, not therapeutic, evidence.

Animal evidence

Dardenne 1982 (PNAS) showed that zinc and certain other metals are required for the biological activity of serum thymic factor, defining thymulin as a metallopeptide. Reggiani 2014 reviews rodent studies in which thymulin or its analog reduced inflammation and pain and in which thymulin gene therapy corrected hormonal abnormalities in athymic (nude) mice. Safieh-Garabedian 2019 reviews rodent neuropathic pain models in which a thymulin related peptide reduced hyperalgesia and inflammatory mediators.

Key studies

Indexed studies of Thymulin
StudyDesign and populationOutcomeGrade
Nonathymulin in rheumatoid arthritis: two double blind, placebo controlled trials1987 PMID 3310925Two randomized, double blind, placebo controlled trials comparing 1, 5, and 10 mg per dayAdults with rheumatoid arthritis5 mg per day improved 56% of patients by global assessment versus 17% on placebo (p below 0.02), with minimal adverse effectsEvidence: Human RCT evidence
Contribution of zinc and other metals to the biological activity of the serum thymic factor1982 PMID 6957870In vitro and in vivo biochemical studyPurified serum thymic factor and rodent T cell assaysZinc binding is required for biological activity, defining thymulin as a metallopeptideEvidence: Animal-only evidence
Physiology and therapeutic potential of the thymic peptide thymulin2014 PMID 24588820Narrative reviewRodent and human physiology studies, thymulin gene therapy in athymic miceSummarizes neuroendocrine regulation, anti-inflammatory and analgesic effects in rodents, and gene therapy results in nude miceEvidence: Animal-only evidence
Targeting inflammatory components in neuropathic pain: The analgesic effect of thymulin related peptide2019 PMID 30503917Review of rodent neuropathic pain studiesRodent models of inflammatory and neuropathic painA thymulin related peptide reduced hyperalgesia and inflammatory mediators in rodentsEvidence: Animal-only evidence

Conditions studied

Conditions with evidence for Thymulin
ConditionGradeNote
Inflammation and inflammatory bowel diseaseNot gradedKPV, thymosin alpha-1, LL-37, VIP, and BPC-157 are marketed as anti-inflammatory peptides. Thymosin alpha-1 has human trials in hepatitis and sepsis outside the United States. KPV has rodent colitis data only. VIP analogs have been studied in small human trials for sarcoidosis and pulmonary hypertension.
Peripheral and small fiber neuropathyEvidence: Animal-only evidenceA thymulin related peptide reduced pain hypersensitivity in rodent models; no human neuropathy study.
Immune support and immune deficiencyEvidence: Animal-only evidenceZinc dependent thymic hormone studied mainly in rodents for immune effects; no human immune function study.
Autoimmune diseaseEvidence: Human RCT evidenceTwo placebo controlled trials in rheumatoid arthritis found global improvement in 56% versus 17% on placebo; never developed further and not approved anywhere.
Chronic painEvidence: Animal-only evidenceA thymulin related peptide reduced inflammatory and neuropathic pain in rodents; no human pain study.

Is Thymulin legal in the United States?

Regulatory: Not eligible for compoundingWADA: WADA prohibited

FDA and compounding status

Thymulin is not an FDA approved drug. FDA lists thymulin acetate in 503A Category 3, meaning it was nominated for compounding without enough supporting information for FDA to evaluate it. Category 3 substances are not covered by FDA's interim compounding policy, and FDA says it would consider taking action against a compounder that uses them. As of the last verification date, thymulin is not on the 503A bulks list, so a US compounding pharmacy has no federal basis to compound it from bulk. It does not appear on FDA's 503B nomination lists, so outsourcing facilities have no route for it either. It was not part of the July 2026 advisory committee review.

WADA status

WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.

Regulatory timeline

No regulatory events recorded.

Full tracker for Thymulin or the category-wide tracker.

Email me when Thymulin's status changes

Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.

What published studies of Thymulin used

Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.

Rheumatoid arthritis trials (Amor 1987): nonathymulin 1, 5, or 10 mg per day, with 5 mg identified as most effective. No dosing has been established for any other use, and no modern human dose finding study exists.

Routes reported

Routes of administration reported for Thymulin
#Route
1Injection (1987 trials)
2Subcutaneous injection and intranasal (as sold, not from published trials)

What are the side effects and interactions of Thymulin?

Side effects

Side effects reported for Thymulin
#Reported side effect
1Minimal adverse effects reported in the 1987 rheumatoid arthritis trials
2No modern human safety data
3Injection site reactions reported anecdotally
4Immunogenicity risk from impurities in unregulated products

Interactions

Interactions reported for Thymulin
#Interaction
1No human interaction data exist
2Zinc status affects activity, so zinc supplements or deficiency could change effect (mechanistic, not clinical, evidence)
3Immunosuppressants: theoretical opposition of effect

Contraindications

Contraindications for Thymulin
#Contraindication
1Pregnancy and breastfeeding (no data)
2Autoimmune disease outside the studied rheumatoid arthritis setting (no data)
3Athletes subject to WADA testing (prohibited at all times under S0)
4Any use requiring an approved product: none exists

How do people access Thymulin legally?

Typical cost: Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.

Access options

  • Not available

    No lawful United States access path identified on the last verified date: it is not FDA approved and is not on the 503A bulks list.

  • Not available

    Not available as an FDA approved product, not nominated for the 503A bulks list, and not eligible for compounding under section 503A or 503B.

  • Not available

    Products labeled research use only are unapproved drugs when sold for human use and are not verified for identity or purity.

Access paths are checked against public regulatory records. Products labeled research use only are never listed.

Compare Thymulin

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. PeptideAgent has not found an FDA warning letter or review that names thymulin. [10] [11] [12]

Being offered does not change the legal status of thymulin. Thymulin is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound it. [6] [7]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [7] [10] [13] [14] [15] [16]

What that means for you

  • A pharmacy that compounds thymulin is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [10] [13]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [16]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [17]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [18] [19]
  • Identity, purity, sterility, and dose accuracy can vary from batch to batch. [7]
  • Insurance rarely covers it, so you usually pay cash.
  • For tested athletes, thymulin is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [8]

If you're going ahead anyway

These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound thymulin, with or without a prescription. [6]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [20] [21] [22]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [12] [22] [23]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [16] [24] [25] [26] [27] [28]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [16]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [20]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [12]
  • Pharmacy: Is this made for me on a prescription written in my name? [23]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [12] [22]
  • Prescriber: What is the legal basis for a pharmacy to compound thymulin? Is it FDA approved or on the 503A bulks list? [6] [16]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [12]

In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [17]

Frequently asked questions

Is thymulin legal in the United States?

It is not FDA approved, has never been nominated for the 503A bulks list (FDA's list of raw ingredients pharmacies may use to compound drugs for individual patients), and has no USP monograph (an official drug quality standard), so no pharmacy can lawfully compound it. It has not been through FDA's Category 2 review (FDA's safety screen of nominated compounding ingredients) because nobody has nominated it. Possession is not a crime, but research chemical products are not for human use. [6] [7]

Does thymulin work for inflammation or autoimmune disease?

The only human evidence is two small double blind trials in rheumatoid arthritis published in 1987, in which 5 mg daily of synthetic thymulin (nonathymulin) improved 56% of patients versus 17% on placebo. That result was never replicated and development stopped. Rodent studies since then show reduced inflammation and pain, but nothing has been tested in modern human trials. [1] [4]

What are the side effects of thymulin?

Largely unknown. The 1987 rheumatoid arthritis trials reported minimal adverse effects, and there are no modern human safety data. Injection site reactions are reported anecdotally. Because products are unregulated, impurity and immunogenicity risk is a practical concern. [1]

How is thymulin taken?

The 1987 trials used 1, 5, or 10 mg of nonathymulin per day by injection, with 5 mg the most effective. Products sold online are subcutaneous or intranasal preparations with no published human dose. Activity depends on zinc binding, which is another reason unregulated products are unpredictable. [1] [2]

How much does thymulin cost?

There is no licensed price. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. [6] [9]

Is thymulin banned by WADA?

It is not named, but section S0 of the WADA Prohibited List prohibits at all times any pharmacological substance with no current approval by a governmental health authority for human use. Thymulin has no approval anywhere, so it falls under S0. [8]

Thymulin vs thymosin alpha-1: what is the difference?

Both are thymus derived immune peptides, but their evidence differs sharply. Thymosin alpha-1 (28 amino acids) has decades of randomized trials in hepatitis B and sepsis and is approved in more than 30 countries. Thymulin (9 amino acids, zinc dependent) has two 1987 rheumatoid arthritis trials and rodent data, with no approval anywhere. Thymulin is also distinct from thymalin, a crude thymus extract used in Russia. [1] [4]

Why does thymulin need zinc?

The peptide is inactive on its own. A 1982 study showed that zinc, and to a lesser extent a few other metals, must bind the peptide for it to have biological activity on T cells, which is why it is sometimes sold as FTS-Zn. Low thymulin activity in zinc deficiency and malnutrition is one of the ways this was discovered. [2] [3]

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Amor B et al. Nonathymulin in rheumatoid arthritis: two double blind, placebo controlled trials. Ann Rheum Dis 1987PubMed 3310925, 1987
  2. [2]Dardenne M et al. Contribution of zinc and other metals to the biological activity of the serum thymic factor. Proc Natl Acad Sci USA 1982PubMed 6957870, 1982
  3. [3]Bach JF, Dardenne M. Thymulin, a zinc-dependent hormone. Med Oncol Tumor Pharmacother 1989PubMed 2657247, 1989
  4. [4]Reggiani PC et al. Physiology and therapeutic potential of the thymic peptide thymulin. Curr Pharm Des 2014PubMed 24588820, 2014
  5. [5]Safieh-Garabedian B et al. Targeting inflammatory components in neuropathic pain: the analgesic effect of thymulin related peptide. Neurosci Lett 2019PubMed 30503917, 2019
  6. [6]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA, 2026
  7. [7]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list, content current as of April 22, 2026)FDA, 2026
  8. [8]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
  9. [9]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
  10. [10]FDA: Compounding inspections, recalls, and other actions (warning letters to compounders)FDA

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, September 29). Thymulin: evidence, legality, and access. https://peptideagent.ai/peptides/thymulin
HTML link
<a href="https://peptideagent.ai/peptides/thymulin">Thymulin: evidence, legality, and access</a>, PeptideAgent, updated September 29, 2026.